Press release
Cystinosis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AVROBIO, Birch Therapeutics, Nacuity Pharmaceuticals
Cystinosis Pipeline constitutes 5+ key companies continuously working towards developing 5+ Cystinosis treatment therapies, analyzes DelveInsight.Cystinosis Overview:
Cystinosis is a rare genetic disorder where the amino acid cystine accumulates in various organs and tissues, including the kidneys, eyes, muscles, liver, pancreas, and brain. It is categorized into three types: nephropathic cystinosis, intermediate cystinosis, and non-nephropathic (ocular) cystinosis. The severity, symptoms, and age of onset vary widely between individuals. Nephropathic cystinosis, the most severe and common form, appears in infancy and often requires a kidney transplant. Non-nephropathic cystinosis only affects the eyes, specifically the corneas.
Cystinosis is caused by mutations in the CTNS gene and inherited in an autosomal recessive pattern, meaning both parents must carry a mutated gene for a child to develop the disorder. While the condition was once fatal at a young age, advancements in cysteamine medication (which reduces cystine levels) and kidney transplants have significantly improved life expectancy, allowing many affected individuals to live into adulthood, and even beyond 50 years. Early diagnosis and treatment can slow disease progression, which can eventually affect all body tissues. Cystinosis affects both males and females equally and is estimated to occur in 1 in 100,000 to 200,000 individuals worldwide. It is found in all ethnic groups.
Request for a detailed insights report on Cystinosis pipeline insights @ https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Cystinosis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Cystinosis Therapeutics Market.
Key Takeaways from the Cystinosis Pipeline Report
DelveInsight's Cystinosis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Cystinosis treatment.
In May 2023, AVROBIO Announced Deal to Sell Its Cystinosis Gene Therapy Program for $87.5 Million.
Key Cystinosis companies such as AVROBIO, Birch Therapeutics, Nacuity Pharmaceuticals, and others are evaluating new drugs for Cystinosis to improve the treatment landscape.
Promising Cystinosis pipeline therapies in various stages of development include AVR RD 04, NP-3, and others.
Cystinosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Cystinosis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystinosis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Cystinosis market.
Download our free sample page report on Cystinosis pipeline insights @ https://www.delveinsight.com/sample-request/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Cystinosis Emerging Drugs
AVR RD 04: AVROBIO
NP-3: Nacuity Pharmaceuticals
Cystinosis Companies
There are over five major companies working on therapies for Cystinosis. Among them, AVROBIO has drug candidates for the condition in the most advanced stage, specifically Phase I/II.
DelveInsight's report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Cystinosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Cystinosis Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Cystinosis Therapies and Key Companies: Cystinosis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Cystinosis Pipeline Therapeutic Assessment
• Cystinosis Assessment by Product Type
• Cystinosis By Stage
• Cystinosis Assessment by Route of Administration
• Cystinosis Assessment by Molecule Type
Download Cystinosis Sample report to know in detail about the Cystinosis treatment market @ Cystinosis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Cystinosis Current Treatment Patterns
4. Cystinosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cystinosis Late-Stage Products (Phase-III)
7. Cystinosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cystinosis Discontinued Products
13. Cystinosis Product Profiles
14. Cystinosis Key Companies
15. Cystinosis Key Products
16. Dormant and Discontinued Products
17. Cystinosis Unmet Needs
18. Cystinosis Future Perspectives
19. Cystinosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Cystinosis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cystinosis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AVROBIO, Birch Therapeutics, Nacuity Pharmaceuticals here
News-ID: 3809441 • Views: …
More Releases from DelveInsight Business Research LLP

Prostate Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic As …
Prostate Cancer Pipeline constitutes 80+ key companies continuously working towards developing 80+ Prostate Cancer treatment therapies, analyzes DelveInsight.
Prostate Cancer Overview:
Prostate cancer occurs when cells in the prostate gland begin to grow uncontrollably. The prostate, which is unique to males, produces some of the fluid found in semen. The primary cause of prostate cancer is changes in DNA, which are triggered by mutations. It is usually diagnosed once the cancer has…

Psoriasis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessme …
Psoriasis Pipeline constitutes 80+ key companies continuously working towards developing 80+ Psoriasis treatment therapies, analyzes DelveInsight.
Psoriasis Overview:
Psoriasis is a chronic inflammatory skin condition that presents with various clinical symptoms and is caused by a combination of genetic, environmental, and immune system factors. It is a non-contagious skin disorder that affects nearly 2% of the global population. The extent of skin involvement can vary from person to person, with cases ranging…

Brain Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Asses …
Brain Cancer Pipeline constitutes 10+ key companies continuously working towards developing 10+ Brain Cancer treatment therapies, analyzes DelveInsight.
Brain Cancer Overview:
Brain metastases occur in 10-16% of patients with metastatic breast cancer and are typically linked to a poor prognosis. The risk of developing brain metastases is higher in younger patients, and in those with estrogen receptor-negative tumors, Her-2+ tumors, or basal-like tumors. Diagnosis is usually made through brain MRI (magnetic resonance…

Gorlin Syndrome Clinical and Non-Clinical Studies, Key Companies, Therapeutic As …
Gorlin Syndrome Pipeline constitutes 5+ key companies continuously working towards developing 5+ Gorlin Syndrome treatment therapies, analyzes DelveInsight.
Gorlin Syndrome Overview:
Gorlin syndrome is a rare inherited condition that impacts multiple organs and tissues in the body. Individuals with this disorder have a significantly increased risk of developing basal cell skin cancer during adolescence or early adulthood, as well as an elevated risk of medulloblastoma (a type of brain cancer) and other…
More Releases for Cystinosis
Cystinosis Treatment Market Analysis, Competitive Assessment and Forecasts to 20 …
The latest Cystinosis Treatment Market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thoroughanalysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. This study can be described as most wide-ranging documentation that comprises all the aspects of the evolving Cystinosis Treatment Market.
Cystinosis…
Cystinosis Treatment Market 2021: Market Landscape, Market Sizing and Forecast u …
Cystinosis Treatment Market research report includes Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years. This study provides information about the sales and revenue during the historic and forecasted period of 2021 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the Cystinosis Treatment market growth.
Cystinosis or Nephropathic cystinosis is a kind…
Cystinosis Treatment Market - Global Industry Insights, Trends, 2026
Cystinosis is a condition characterized by accumulation of the cystine (amino acid) within cells. High amount of cystine damages cells and often forms crystals that can damage tissues and organs. The eyes and kidneys are mainly susceptible to damage; however, the pancreas, muscles, testes, and thyroid can also be affected. Cystinosis is categorized into three different types; nephropathic, non-nephropathic or ocular, and intermediate cystinosis. Nephropathic (infantile) cystinosis is the most…
Nephropathic Cystinosis Treatment Market– Growth Opportunities & Technology De …
The report " Nephropathic Cystinosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025", has been prepared based on an in-depth market analysis with inputs from industry experts.
The main objective of this report is to define, describe, and forecast the global “Nephropathic Cystinosis Treatment” market on the basis of types of applications, major sectors, deployment models, organization size, and regions. The report contains an…
Cystinosis Disease Therapeutics Market: Regional Markets, Technology, Types, and …
Cystinosis is a rare disease and characterized by accumulation of cystine (a building block of proteins) inside cells. Increase in cystine damages cells and frequently forms crystals that can develop and cause issues in numerous organs and tissues. The kidneys and eyes are particularly defenseless to the damage. Muscles, thyroid, pancreas, and testicles could also be affected. Nephropathic cystinosis, intermediate cystinosis, and non-nephropathic cystinosis are the three types of cystinosis.…
Nephropathic Cystinosis Treatment Market Estimated to Flourish by 2025
Nephropathic cystinosis is the leading lysosomal storage disorder caused due to malfunctioning lysosomal membrane transfusion, and it assists as a prototype for a small group of lysosomal transportation disorders. The disease leads to intracellular growth of cysteine in all tissues and organs. Nephropathic cystinosis is an uncommon autosomal recessive disorder with lysosomal storing of the amino acid cysteine due to a deficiency in the membrane transfusion protein, cystinosis. Meanwhile the…